[Fracture prevention in metastatic prostate cancer]

Patients with metastatic prostate cancer are living longer than they used to, thanks to a wider range of therapeutic options. This means that an increasing number of men will receive long-term treatment with anti-hormonal therapy - androgen-deprivation therapy (ADT) - and the risk of side effects from this therapy is increasing. A relevant decrease in bone density is increasingly seen in patients receiving ADT, which means that a disproportionate increase in risk of fractures is seen in aging patients. Urologists are confronted with these patients in clinical practice. The question is how urologist-care for these patients is organised in the Netherlands. A survey among urologists in the Netherlands revealed that there is great diversity in how they think and act, and that there is a need for national guidelines and additional training on this subject.